[go: up one dir, main page]

WO2013170072A3 - Composés pour le traitement de troubles neurologiques - Google Patents

Composés pour le traitement de troubles neurologiques Download PDF

Info

Publication number
WO2013170072A3
WO2013170072A3 PCT/US2013/040408 US2013040408W WO2013170072A3 WO 2013170072 A3 WO2013170072 A3 WO 2013170072A3 US 2013040408 W US2013040408 W US 2013040408W WO 2013170072 A3 WO2013170072 A3 WO 2013170072A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
nmda receptor
treatment
neurological disorders
intended
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/040408
Other languages
English (en)
Other versions
WO2013170072A2 (fr
Inventor
Kamalesh Babu Ruppa POORNACHARY
Scott J. MYERS
George Walter Koszalka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NeurOp Inc
Original Assignee
NeurOp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NeurOp Inc filed Critical NeurOp Inc
Publication of WO2013170072A2 publication Critical patent/WO2013170072A2/fr
Publication of WO2013170072A3 publication Critical patent/WO2013170072A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Dans un aspect, l'invention concerne des modulateurs d'un récepteur NMDA, des dérivés de ceux-ci, et des composés associés, qui sont utiles en tant qu'inhibiteurs du récepteur NMDA ; des procédés synthétiques pour fabriquer les composés ; des compositions pharmaceutiques comprenant les composés ; et des méthodes de traitement ou de prévention de troubles neurologiques et psychiatriques associés à un dysfonctionnement du récepteur NMDA à l'aide des composés et des compositions. Cet abrégé est destiné être un outil de balayage dans des fins de recherche dans la technique particulière et n'est pas destiné à être limitant de la présente invention.
PCT/US2013/040408 2012-05-09 2013-05-09 Composés pour le traitement de troubles neurologiques Ceased WO2013170072A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261645040P 2012-05-09 2012-05-09
US61/645,040 2012-05-09

Publications (2)

Publication Number Publication Date
WO2013170072A2 WO2013170072A2 (fr) 2013-11-14
WO2013170072A3 true WO2013170072A3 (fr) 2014-02-27

Family

ID=49551464

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/040408 Ceased WO2013170072A2 (fr) 2012-05-09 2013-05-09 Composés pour le traitement de troubles neurologiques

Country Status (1)

Country Link
WO (1) WO2013170072A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9040581B1 (en) 2013-02-21 2015-05-26 The Florida State University Research Foundation, Inc. Methods of treatment using D-serine
RU2017107521A (ru) * 2014-08-27 2018-10-01 Ф. Хоффманн-Ля Рош Аг Замещенные производные азетидина в качестве лигандов рецепторов следовых аминов taar
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
US20190298705A1 (en) 2016-06-08 2019-10-03 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
CN107793362B (zh) * 2016-08-30 2022-04-22 江苏恩华药业股份有限公司 一种苯基哒嗪酮类衍生物的合成及其应用
CN110099898B (zh) 2016-10-24 2023-07-25 优曼尼蒂治疗公司 化合物及其用途
CN110392833A (zh) 2017-01-06 2019-10-29 优曼尼蒂治疗公司 治疗神经病症的方法
WO2019012001A1 (fr) 2017-07-12 2019-01-17 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2019084157A1 (fr) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Composés et utilisations de ces composés
CN112312913B (zh) 2018-03-23 2024-03-08 詹森药业有限公司 化合物和其用途
US20210284633A1 (en) 2018-07-02 2021-09-16 Syngenta Crop Protection Ag 3-(2-thienyl)-5-(trifluoromethyl)-1,2,4-oxadiazole derivatives as agrochemical fungicides
CR20210181A (es) 2018-09-19 2021-07-01 Biogen Ma Inc Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
CN113906019A (zh) 2019-01-24 2022-01-07 优曼尼蒂治疗公司 化合物及其用途
US11484519B2 (en) 2019-03-07 2022-11-01 Florida State University Research Foundation, Inc. D-serine inhibit neuroinflammation due to a brain injury
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
JP7781391B2 (ja) * 2021-04-22 2025-12-08 カヨセラ インコーポレイテッド 複素環式化合物及びその使用
JP2024533182A (ja) 2021-09-02 2024-09-12 エモリー ユニバーシティー 酸性ｐＨで増強された効力を有するＮ－メチル－Ｄ－アスパラギン酸受容体のＧｌｕＮ２Ｂサブユニット選択的アンタゴニスト

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4403037A (en) * 1980-10-10 1983-09-06 American Hoechst Corporation Erythrocyte preparations and use thereof in hemagglutination tests
US5264125A (en) * 1989-09-08 1993-11-23 Ionics' Incorporated Process for manufacturing continuous supported ion selective membranes using non-polymerizable high boiling point solvents
US20100004261A1 (en) * 2004-12-30 2010-01-07 Richard Apodaca Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
US20110160223A1 (en) * 2008-05-09 2011-06-30 Dingledine Raymond J NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4403037A (en) * 1980-10-10 1983-09-06 American Hoechst Corporation Erythrocyte preparations and use thereof in hemagglutination tests
US5264125A (en) * 1989-09-08 1993-11-23 Ionics' Incorporated Process for manufacturing continuous supported ion selective membranes using non-polymerizable high boiling point solvents
US20100004261A1 (en) * 2004-12-30 2010-01-07 Richard Apodaca Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
US20110160223A1 (en) * 2008-05-09 2011-06-30 Dingledine Raymond J NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders

Also Published As

Publication number Publication date
WO2013170072A2 (fr) 2013-11-14

Similar Documents

Publication Publication Date Title
WO2013170072A3 (fr) Composés pour le traitement de troubles neurologiques
WO2012118563A3 (fr) Analogues de 6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamide en tant que modulateurs allostériques négatifs de mglur5 et procédé pour les préparer et les utiliser
HK1231471A1 (zh) 6-杂芳氧基-和6芳氧基-喹啉-2-甲酰胺及其用途
WO2014055928A3 (fr) Analogues de n-(3-(pyrimidin-4-yl)phényl) substitué utilisés en tant qu'inhibiteurs de récepteur tyrosine kinase btk
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
WO2014145214A3 (fr) Inhibiteurs de prmt5 et leurs procédés d'utilisation
HK1246286A1 (zh) Lrrk2抑制剂及其制备和使用方法
WO2014055934A3 (fr) Analogues de n-(3-(pyrimidin-4-yl)phényl) substitué utilisés en tant qu'inhibiteurs de récepteur tyrosine kinase btk
WO2016044189A8 (fr) Méthodes de traitement du cancer faisant appel à un antagoniste se liant à l'axe pd-1 et à des antagonistes se liant à l'il-17
MY167245A (en) Compounds and compositions as c-kit kinase inhibitors
IN2014DN09805A (fr)
WO2013177420A3 (fr) Procédés et compositions pour le traitement des leucémies lymphoblastiques bcr-abl positives
WO2014155300A3 (fr) Dérivés pyrimidine aminée substitués en tant qu'inhibiteurs de tak-1
WO2015200682A8 (fr) Analogues substitués de 4-alcoxypicolinamide en tant que modulateurs allostériques négatifs de mglur5
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
HK1220370A1 (zh) 取代的吉西他滨二环酰胺类似物及使用其治疗的方法
PH12017500089B1 (en) Aldosterone synthase inhibitors
PH12017500595B1 (en) Aldosterone synthase inhibitors
TW201613884A (en) Selective NR2B antagonists
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
EP2575461A4 (fr) 6-méthylnicotinamides substitués utiles en tant que modulateurs allostériques positifs de mglur5
WO2012125732A8 (fr) Imadazapyrinidin-5(6h)-ones substituées en tant que modulateurs allostériques des récepteurs mglur5
WO2013155465A8 (fr) Dérivés de xanthine substituée
MX2012003394A (es) Analogos de la nicotinamida de o-bencilo como moduladores alostéricos positivos del mglur5.
WO2013048949A3 (fr) Antagonistes du nr2b sélectifs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13788154

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13788154

Country of ref document: EP

Kind code of ref document: A2